PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs

News   Jun 21, 2018 | Original story from PhoreMost

 
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs

Dr Chris Torrance, CEO at PhoreMost Ltd

 
 
 

RELATED ARTICLES

CRISPR Screening Reveals Sickle Cell Disease Target

News

A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.

READ MORE

UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPO

News

MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).

READ MORE

Diagnosis and Treatment of Heart and Circulatory Diseases a Top Priority for the UK

News

NHS commits to a new focus around heart and circulatory diseases in 10 year plan

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy